Eric Tycksen

Eric Tycksen

Auto-generated profile, based on publicly available information

Eric Tycksen

Genome Technology Access Center, Washington University School of Medicine, St. Louis, Missouri, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2013 in Nature Medicine
Verified
Journal Article
Open access
PDF file
PRPaul F Robbins
Paul F Robbins
YLYong-Chen Lu
Yong-Chen Lu
MEMona El-Gamil
Mona El-Gamil
YLYong F Li
Yong F Li
CGColin Gross
Colin Gross
SRSteven A Rosenberg
Steven A Rosenberg
Identifying tumor-associated T cell epitopes can be laborious. Robbins et al. now report that they used whole-exome sequence data to identify mutated peptides from tumor antigens that are recognized by tumor-infiltrating T cells from patients with melanoma who experienced therapy-associated tumor regressions. The method will contribute to the identification of new tumor-specific epitopes that may further the development of effective T cell therapies for the treatment of patients with melanoma as well as a variety of additional malignancies. Substantial regressions of metastatic lesions have been observed in up to 70% of patients with melanoma who received adoptively transferred autologous tumor-infiltrating lymphocytes (TILs) in phase 2 clinical trials1,2. In addition, 40% of patients treated in a recent trial experienced complete regressions of all measurable lesions for at least 5 years following TIL treatment3. To evaluate the potential association between the ability of TILs to mediate durable regressions and their ability to recognize potent antigens that presumably include mutated gene products, we developed a new screening approach involving mining whole-exome sequence data to identify mutated proteins expressed in patient tumors. We then synthesized and evaluated candidate mutated T cell epitopes that were identified using a major histocompatibility complex–binding algorithm4 for recognition by TILs. Using this approach, we identified mutated antigens expressed on autologous tumor cells that were recognized by three bulk TIL lines from three individuals with melanoma that were associated with objective tumor regressions following adoptive transfer. This simplified approach for identifying mutated antigens recognized by T cells avoids the need to generate and laboriously screen cDNA libraries from tumors and may represent a generally applicable method for identifying mutated antigens expressed in a variety of tumor types.

1 October 2019 in Molecular Cell
Verified
Journal Article
Closed access
SPSamantha K. Powers
Samantha K. Powers
AHAlex S. Holehouse
Alex S. Holehouse
DKDavid Korasick
David Korasick
KSKatherine H. Schreiber
Katherine H. Schreiber
NCNatalie Clark
Natalie Clark
LSLucia C. Strader
Lucia C. Strader

5 September 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZZZhe Zhu
Zhe Zhu
MGMatthew J. Gorman
Matthew J. Gorman
LMLisa D. McKenzie
Lisa D. McKenzie
JCJiani N. Chai
Jiani N. Chai
CHChristopher G. Hubert
Christopher G. Hubert
MCMilan G. Chheda
Milan G. Chheda
Glioblastoma is a highly lethal brain cancer that frequently recurs in proximity to the original resection cavity. We explored the use of oncolytic virus therapy against glioblastoma with Zika virus (ZIKV), a flavivirus that induces cell death and differentiation of neural precursor cells in the developing fetus. ZIKV preferentially infected and killed glioblastoma stem cells (GSCs) relative to differentiated tumor progeny or normal neuronal cells. The effects against GSCs were not a general property of neurotropic flaviviruses, as West Nile virus indiscriminately killed both tumor and normal neural cells. ZIKV potently depleted patient-derived GSCs grown in culture and in organoids. Moreover, mice with glioblastoma survived substantially longer and at greater rates when the tumor was inoculated with a mouse-adapted strain of ZIKV. Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thus, genetically modified strains that further optimize safety could have therapeutic efficacy for adult glioblastoma patients.

30 September 2020 in Gastroenterology
Verified
Journal Article
Closed access
AMAaron A. May-Zhang
Aaron A. May-Zhang
ETEric Tycksen
Eric Tycksen
ASAustin N. Southard-Smith
Austin N. Southard-Smith
KDKaren K. Deal
Karen K. Deal
JBJoseph T. Benthal
Joseph T. Benthal
ESE Michelle Southard-Smith
E Michelle Southard-Smith

26 April 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
SPSamira Parhizkar
Samira Parhizkar
GGGrace Gent
Grace Gent
YCYun Chen
Yun Chen
NRNicholas Rensing
Nicholas Rensing
MGMaud Gratuze
Maud Gratuze
DHDavid Holtzman
David Holtzman
Sleep loss is associated with cognitive decline in the aging population and is a risk factor for Alzheimer’s disease (AD). Considering the crucial role of immunomodulating genes such as that encoding the triggering receptor expressed on myeloid cells type 2 (TREM2) in removing pathogenic amyloid-β (Aβ) plaques and regulating neurodegeneration in the brain, our aim was to investigate whether and how sleep loss influences microglial function in mice. We chronically sleep-deprived wild-type mice and the 5xFAD mouse model of cerebral amyloidosis, expressing either the humanized TREM2 common variant, the loss-of-function R47H AD-associated risk variant, or without TREM2 expression. Sleep deprivation not only enhanced TREM2-dependent Aβ plaque deposition compared with 5xFAD mice with normal sleeping patterns but also induced microglial reactivity that was independent of the presence of parenchymal Aβ plaques. We investigated lysosomal morphology using transmission electron microscopy and found abnormalities particularly in mice without Aβ plaques and also observed lysosomal maturation impairments in a TREM2-dependent manner in both microglia and neurons, suggesting that changes in sleep modified neuro-immune cross-talk. Unbiased transcriptome and proteome profiling provided mechanistic insights into functional pathways triggered by sleep deprivation that were unique to TREM2 and Aβ pathology and that converged on metabolic dyshomeostasis. Our findings highlight that sleep deprivation directly affects microglial reactivity, for which TREM2 is required, by altering the metabolic ability to cope with the energy demands of prolonged wakefulness, leading to further Aβ deposition, and underlines the importance of sleep modulation as a promising future therapeutic approach.

30 September 2021 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
SCSangappa B Chadchan
Sangappa B Chadchan
PPPooja Popli
Pooja Popli
CAChandrasekhar R Ambati
Chandrasekhar R Ambati
ETEric Tycksen
Eric Tycksen
SHSang Jun Han
Sang Jun Han
RKRamakrishna Kommagani
Ramakrishna Kommagani
Worldwide, ∼196 million are afflicted with endometriosis, a painful disease in which endometrial tissue implants and proliferates on abdominal peritoneal surfaces. Theories on the origin of endometriosis remained inconclusive. Whereas up to 90% of women experience retrograde menstruation, only 10% develop endometriosis, suggesting that factors that alter peritoneal environment might contribute to endometriosis. Herein, we report that whereas some gut bacteria promote endometriosis, others protect against endometriosis by fermenting fiber to produce short-chain fatty acids. Specifically, we found that altered gut microbiota drives endometriotic lesion growth and feces from mice with endometriosis contained less of short-chain fatty acid and n-butyrate than feces from mice without endometriosis. Treatment with n-butyrate reduced growth of both mouse endometriotic lesions and human endometriotic lesions in a pre-clinical mouse model. Mechanistic studies revealed that n-butyrate inhibited human endometriotic cell survival and lesion growth through G-protein–coupled receptors, histone deacetylases, and a GTPase activating protein, RAP1GAP. Our findings will enable future studies aimed at developing diagnostic tests, gut bacteria metabolites and treatment strategies, dietary supplements, n-butyrate analogs, or probiotics for endometriosis.